Neurology represents a rapidly expanding segment in the
Intravenous Immunoglobulin (IVIg) Market with multiple approved and emerging indications. Chronic inflammatory demyelinating polyneuropathy remains the leading neurological indication with established clinical efficacy. Multifocal motor neuropathy, Guillain-Barré syndrome, and myasthenia gravis represent additional approved uses.
The
Intravenous Immunoglobulin (IVIg) Market explores off-label applications in multiple sclerosis, stiff-person syndrome, and autoimmune encephalitis. Clinical trials investigate optimal dosing regimens and long-term maintenance protocols. Biomarker research aims to identify patients most likely to respond to immunoglobulin therapy.
FAQ
Q: Which neurological conditions use IVIg? A: CIDP, multifocal motor neuropathy, Guillain-Barré syndrome, myasthenia gravis, and dermatomyositis.
Q: How does IVIg work in neurology? A: It modulates immune responses, neutralizes autoantibodies, and reduces complement-mediated nerve damage.
Q: What research is ongoing? A: Dosing optimization, biomarker identification, and new indications in autoimmune neurological conditions.
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
